NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.
Enhancingthe body’s healing response
Rebalancingthe immune system
Unlockingthe power of VSELs
NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.
NeoStem’s Investigational Targeted Cancer Immunotherapy For Late Stage Melanoma (2 minute)
See how NeoStem's Phase III investigational targeted cancer immunotherapy, NBS20 (eltrapuldencel-T), is created and administered. The product candidate is being evaluated for the treatment of patients suffering from late stage malignant melanoma.
News + EventsNeoStem Ranked as One of the Fastest Growing Companies in New York City October 13, 2014 - Learn MoreNeoStem Announces USAN Approval of Generic Name ‘Eltrapuldencel-T’ for Investigational Patient-Specific Targeted Cancer Immunotherapy October 6, 2014 - Learn More
We often hear that an educated patient is an empowered patient, and this summer I heard an inspiring story .... Read More